Crowdfunding
TrippBio announces new crowdfunding campaign
We’re excited to announce that we are initiating a Crowdfunding campaign on StartEngine. Due to our recent successes we’re looking to continue our growth and are expanding our vision through an upcoming capital fundraising round. This is a really exciting moment for us as we reflect on how far we’ve come to get to this point where we’re looking to bring on new investors. The best part is through StartEngine’s platform, we’re able to host an equity crowdfunding campaign and open our fundraising round to our own community!
What exactly is equity crowdfunding?
Regulation Crowdfunding gives eligible companies of all types an opportunity to raise capital from the public. Investors hold partial ownership in the company and have the opportunity to benefit if the company does well. In the past, a startup could only offer and sell its securities to accredited investors and then only if it complied with complex federal and state registration requirements. Under the JOBS Act, the general public can now invest in capital raising by start-up companies.
Why should I invest?
PanCytoVir™ Outperforms Tamiflu in Broad-Spectrum Antiviral Trial
PanCytoVir™ is a broad-spectrum antiviral that has demonstrated positive Phase 2 results in COVID-19 patients.* Based on our studies, it has shown superior efficacy compared to Tamiflu in animal models of influenza infection, exhibiting potent activity against RSV.
TrippBio Secures $1.38M, Advances Toward Phase 3 in Antiviral Development
TrippBio operates in a large market with a need for affordable antiviral treatments. We’ve raised over $1.38M, achieved positive clinical results, and are in FDA discussions for entering Phase 3 trials.*
*The product described herein is currently in development and undergoing clinical trials. Results from clinical trials are not indicative of future performance and do not guarantee regulatory approval or market success. The product has not been approved by the U.S. Food and Drug Administration (FDA) and is not available for sale. Any forward-looking statements regarding potential outcomes should not be construed as assurances of regulatory approval or commercial availability.
TrippBio Advances Life-Saving Antivirals, Targets Unmet Global Needs
Our mission is to deliver life-saving, accessible treatments. Funds raised will help advance clinical trials as we aim to address large, unmet medical needs in global healthcare.
What's next:
Learn More
You’ll find more information on our business and growth plan, financials, investor benefits, and a lot more on our campaign page.
Sign Up
Sign-up for your free StartEngine account and become a contributor.
Follow Campaign
Hit the “Follow” button on our campaign page to follow along our journey and receive updates throughout our campaign
Introduction to TrippBio
As a company, TrippBio is dedicated to enhancing the healthcare treatment industry and changing lives across the globe. Our goal is to bring life-saving treatments to patients worldwide. TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to treat viral pathogens like influenza, RSV, and COVID-19.
